A way forward when the road appeared to have ended
For patients whose cancers had stopped responding to every available treatment, medicine has long offered little more than diminishing hope. This week in London, researchers announced that amivantamab — a triple-action drug developed by Johnson & Johnson and tested across eleven countries — eliminated tumors entirely in 15 of 102 patients with treatment-resistant head and neck cancer, with responses also observed in lung cancer. The findings, to be presented at the American Society of Clinical Oncology's annual meeting in Chicago, carry the rare weight of genuine surprise in a field accustomed to incremental progress.
- Patients with advanced head and neck cancers — resistant to both chemotherapy and immunotherapy — had effectively run out of road, making this trial their last viable option.
- In 43 of 102 cases, tumors shrank or vanished; in 15 of those, they disappeared completely — results a leading oncologist described as 'unprecedentedly strong.'
- The drug's positive effects extended beyond head and neck cancer into lung cancer patients, hinting at a mechanism broad enough to reshape treatment across multiple cancer types.
- With roughly 60 active clinical trials underway globally, the pharmaceutical and research communities are moving quickly to understand how far amivantamab's reach extends.
- The central question has shifted from whether the drug works to how fast it can clear regulatory pathways and reach the patients who have no other options left.
In London this week, oncologists revealed results from a large international trial that has drawn serious attention across the cancer research community. The drug, amivantamab — developed by Johnson & Johnson — was tested in eleven countries on patients whose cancers had stopped responding to chemotherapy and immunotherapy alike. For these individuals, the standard paths forward had closed.
Among 102 patients with head and neck cancer — the world's sixth most common cancer — tumors shrank or disappeared in 43 cases. Fifteen patients saw complete eradication. Kevin Harrington, a professor of biological cancer therapies at the Institute of Cancer Research in London, called the outcomes 'unprecedentedly strong responses,' language that carries particular weight in a field where modest gains are often the ceiling.
The trial also produced encouraging results in lung cancer patients, suggesting amivantamab's mechanism may apply more broadly than a single disease. The drug is currently being evaluated in approximately 60 clinical trials worldwide, reflecting how seriously the research community is treating these early findings.
The results are set to be presented at the American Society of Clinical Oncology's annual meeting in Chicago, an event likely to accelerate the drug's development pathway. Amivantamab remains years from widespread availability, but for patients whose disease had become untreatable, the data offers something that had seemed out of reach: a direction forward.
In London this week, oncologists announced results from a sprawling international trial that has caught the attention of cancer researchers worldwide. The drug in question, amivantamab, was tested across eleven countries on a population of patients whose cancers had stopped responding to the treatments that usually work—chemotherapy, immunotherapy, the standard arsenal. For these people, options had narrowed considerably. What the trial found was striking enough to warrant presentation at the American Society of Clinical Oncology's annual meeting in Chicago on Sunday.
Amivantamab is a triple-action cancer vaccine developed by Johnson & Johnson. The mechanism is complex, but the results are not: in a group of 102 patients with head and neck cancer—a disease that ranks as the world's sixth most common cancer—tumors either shrank or vanished entirely in 43 cases. Of those, 15 patients saw their tumors disappear completely. These were not people with early-stage disease or cancers still responsive to conventional treatment. These were patients whose disease had become resistant to both chemotherapy and immunotherapy, for whom the usual paths forward had closed.
Kevin Harrington, a professor of biological cancer therapies at the Institute of Cancer Research in London and a consultant oncologist at the Royal Marsden NHS foundation trust, described the findings in terms that signal genuine surprise in the medical community. He called them "unprecedentedly strong responses" in patients whose cancers had developed resistance to multiple drug classes. That language matters. In oncology, where incremental gains are often celebrated, the word "unprecedented" carries weight.
The trial was not limited to head and neck cancers. Researchers observed similar positive outcomes in patients with lung cancer, suggesting the drug's mechanism may have broader application across cancer types. This matters because it hints at a more general principle at work—not a treatment tailored narrowly to one disease, but something with wider reach.
Amivantamab is currently being evaluated in approximately 60 clinical trials globally, a sign that the pharmaceutical and research communities are taking seriously what these early results suggest. The drug is still in development, still being tested, still years away from widespread availability. But for patients in those trials, and for the oncologists treating them, the data presented this week represents something that had seemed unlikely: a way forward when the road appeared to have ended.
The presentation at the American Society of Clinical Oncology meeting will likely accelerate interest in the drug's development pathway. For patients with advanced cancers that have exhausted standard options, the question now becomes not whether amivantamab works—the trial suggests it does, at least for some—but how quickly it can move through the remaining regulatory steps and into clinical practice. The human stakes are clear: people whose disease had become untreatable may now have a treatment option.
Notable Quotes
These are unprecedentedly strong responses in patients whose disease has become resistant to both chemotherapy and immunotherapy— Kevin Harrington, professor of biological cancer therapies at the Institute of Cancer Research, London
The Hearth Conversation Another angle on the story
When you say the tumors disappeared entirely in fifteen patients, what does that actually mean for someone living with that diagnosis?
It means no detectable cancer remaining. In oncology, that's called a complete response. For patients who'd already failed chemotherapy and immunotherapy, it's the outcome they'd stopped expecting.
Why does it matter that this worked in both head and neck cancers and lung cancers?
Because it suggests the drug isn't fighting a specific cancer type—it's fighting something more fundamental about how these resistant tumors work. That's the difference between a narrow fix and a broader tool.
The article mentions sixty clinical trials. Why so many?
Johnson & Johnson is testing it against different cancer types, different patient populations, different combinations with other drugs. They're mapping the boundaries of what it can do.
For someone reading this who has cancer, what's the realistic timeline?
Honest answer? Years. These results are promising, but the drug still needs to complete trials, get regulatory approval, then be manufactured and distributed. Hope, yes. Immediate access, no.
What makes these results "unprecedented" rather than just "good"?
Patients whose cancers had resisted both chemotherapy and immunotherapy are essentially out of options. Getting forty-three responses out of 102 in that population—that's not incremental progress. That's a door opening where there wasn't one before.